Constellation Energy Corporation vs Eli Lilly And Co — how do they compare? Constellation Energy Corporation trades at $257.84 (market cap $91.57B), while Eli Lilly And Co trades at $1,152.5 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 11.2× Constellation Energy Corporation's market cap, and Constellation Energy Corporation pays the higher dividend (0.67%). Which is the better fit depends on your goals.
| CEG | LLY | |
|---|---|---|
Market Cap | $91.57B | $1.03T |
Sector | Energy | Health |
52-Week High | $403.95 | $1.24K |
52-Week Low | $236.50 | $625.65 |
Enterprise Value | $113.24B | $1.07T |
Dividend Yield | 0.67% | 0.6% |
Signals from Pluang's Aura AI — not financial advice
Constellation Energy (CEG) trades at $257.57, up 2.46% today, showing strong momentum despite a bearish technical signal. The stock benefits from robust fundamentals with 2025 revenue of $25.53B and net income of $2.32B, supported by a 70% analyst buy rating and consensus price target of $343.50. Recent news highlights CEG's strategic positioning to capitalize on rising AI-driven electricity demand and nuclear power resurgence.
The outlook remains positive with CEG positioned as a key beneficiary of growing electricity demand from AI and data centers. Investment opportunities include strong earnings growth projections and favorable valuation metrics. Risks include execution challenges in capacity expansion and potential regulatory changes affecting utility operations.
Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.
The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.
Trailing returns across standard periods
Latest headlines on both assets
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →